A new era for radiolabeled antibodies in cancer?
- 1 October 1999
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 11 (5) , 563-569
- https://doi.org/10.1016/s0952-7915(99)00017-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1998
- The Development of Monoclonal Antibodies for the Therapy of CancerCritical Reviews™ in Eukaryotic Gene Expression, 1998
- Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using131I-LYM-1 AntibodyCancer Biotherapy & Radiopharmaceuticals, 1998
- Update: A Revolution in the Treatment of Non-Hodgkin's LymphomaCancer Biotherapy & Radiopharmaceuticals, 1998
- Increased survival associated with radiolabeled lym-1 therapy for non-hodgkin's lymphoma and chronic lymphocytic leukemiaCancer, 1997
- Trials and tribulations: Oncological antibody imaging comes to the foreSeminars in Nuclear Medicine, 1997
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasThe Lancet, 1995
- Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow SupportNew England Journal of Medicine, 1993
- Treatment of B cell malignancies with131I LYM-1 monoclonal antibodiesInternational Journal of Cancer, 1988